Lucid Diagnostics Inc. - Common Stock, par value $0.001 per share (LUCD) Institutional Ownership

13F Institutional Holders and Ownership History from Q4 2021 to Q4 2025

Type / Class
Equity / Common Stock, par value $0.001 per share
Symbol
LUCD on Nasdaq
Shares outstanding
141,152,375
Price per share
$1.19
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
25,561,872
Total reported value
$27,832,393
% of total 13F portfolios
0%
Share change
-173,804
Value change
+$167,194
Number of holders
61
Price from insider filings
$1.19
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Lucid Diagnostics Inc. - Common Stock, par value $0.001 per share (LUCD) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
PAVmed Inc. 28% -2.9% $46,192,115 38,816,903 0% PAVmed Inc. 03 Feb 2026
Ayrton Capital LLC 2% $1,596,645 1,200,485 Ayrton Capital LLC 31 Dec 2024

As of 31 Dec 2025, 61 institutional investors reported holding 25,561,872 shares of Lucid Diagnostics Inc. - Common Stock, par value $0.001 per share (LUCD). This represents 18% of the company’s total 141,152,375 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Lucid Diagnostics Inc. - Common Stock, par value $0.001 per share (LUCD) together control 18% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
VANGUARD GROUP INC 3.5% 4,968,608 +9.8% 0% $5,415,782
BlackRock, Inc. 3.1% 4,312,638 +18% 0% $4,700,775
Aberdeen Group plc 2.4% 3,457,894 +38% 0.01% $3,769,104
Two Seas Capital LP 2.1% 3,000,000 0% 0.19% $3,270,000
GEODE CAPITAL MANAGEMENT, LLC 1.4% 2,026,827 +21% 0% $2,209,465
STATE STREET CORP 0.96% 1,352,955 +33% 0% $1,474,721
PERKINS CAPITAL MANAGEMENT INC 0.8% 1,126,000 -0.09% 0.97% $1,227,340
WELLS FARGO & COMPANY/MN 0.65% 919,479 +29% 0% $1,002,232
RENAISSANCE TECHNOLOGIES LLC 0.59% 826,527 +181% 0% $900,914
Lido Advisors, LLC 0.27% 383,082 0% 0% $386,913
JANE STREET GROUP, LLC 0.26% 362,615 +1123% 0% $395,250
Squarepoint Ops LLC 0.24% 342,883 +1872% 0% $373,742
UBS Group AG 0.22% 309,494 +113% 0% $337,348
GOLDMAN SACHS GROUP INC 0.2% 289,275 -48% 0% $315,310
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 0.16% 224,921 +29% 0% $245,164
Bank of New York Mellon Corp 0.14% 202,799 -1.5% 0% $221,051
XML Financial, LLC 0.13% 178,795 0% 0.02% $194,887
LPL Financial LLC 0.1% 141,391 +0.15% 0% $154,116
BARCLAYS PLC 0.1% 141,167 +41% 0% $153,872
MORGAN STANLEY 0.07% 102,598 +5% 0% $111,832
Nantahala Capital Management, LLC 0.07% 94,541 0% 0.01% $103,050
Nuveen, LLC 0.06% 90,234 0% 0% $98,355
DEUTSCHE BANK AG\ 0.06% 80,355 0% $87,587
NEW YORK STATE COMMON RETIREMENT FUND 0.04% 58,700 0% 0% $63,983
Sargent Investment Group, LLC 0.04% 54,030 0% 0.01% $58,893

Institutional Holders of Lucid Diagnostics Inc. - Common Stock, par value $0.001 per share (LUCD) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 25,561,872 $27,832,393 +$167,194 $1.09 61
2025 Q3 35,149,381 $35,503,869 +$16,337,032 $1.01 83
2025 Q2 18,928,571 $21,732,070 +$10,810,145 $1.15 70
2025 Q1 9,361,697 $13,942,565 +$9,083,709 $1.49 47
2024 Q4 3,301,334 $2,700,118 +$681,674 $0.82 31
2024 Q3 2,453,404 $1,999,216 +$373,764 $0.82 27
2024 Q2 1,993,582 $1,635,840 -$60,859 $0.82 31
2024 Q1 2,071,200 $1,687,992 +$173,028 $0.81 26
2023 Q4 1,747,190 $2,463,380 -$132,319 $1.41 23
2023 Q3 1,915,159 $2,240,076 +$59,719 $1.17 23
2023 Q2 1,863,743 $2,590,935 +$131,895 $1.39 16
2023 Q1 1,768,504 $2,486,590 -$200,456 $1.40 18
2022 Q4 1,914,916 $2,603,465 -$579,811 $1.36 21
2022 Q3 2,303,350 $3,522,489 -$263,904 $1.53 20
2022 Q2 2,455,369 $5,552,000 -$914,258 $2.26 23
2022 Q1 2,705,630 $9,090,000 -$2,655,787 $3.36 30
2021 Q4 3,308,904 $17,765,000 +$14,803,000 $5.37 35